4//SEC Filing
Ericson William W. 4
Accession 0001328143-21-000091
CIK 0001328143other
Filed
Nov 23, 7:00 PM ET
Accepted
Nov 24, 4:09 PM ET
Size
24.4 KB
Accession
0001328143-21-000091
Insider Transaction Report
Form 4
Ericson William W.
Director10% Owner
Transactions
- Disposition from Tender
Common Stock
2021-11-24−10,000→ 0 total - Disposition from Tender
Common Stock
2021-11-24−4,031,804→ 0 total(indirect: MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP) - Disposition from Tender
Common Stock
2021-11-24−3,146→ 0 total(indirect: MDV ENF VII (B), L.P.) - Disposition to Issuer
Stock Option (Right to Buy)
2021-11-24−10,000→ 0 totalExercise: $4.80Exp: 2029-06-04→ Common Stock (10,000 underlying) - Disposition from Tender
Common Stock
2021-11-24−265,150→ 0 total(indirect: MDV VII, L.P.) - Disposition from Tender
Common Stock
2021-11-24−287,992→ 0 total(indirect: MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.) - Disposition to Issuer
Stock Option (Right to Buy)
2021-11-24−10,000→ 0 totalExercise: $2.70Exp: 2030-06-02→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-11-24−10,000→ 0 totalExercise: $5.21From: 2022-06-02Exp: 2031-06-01→ Common Stock (10,000 underlying) - Disposition from Tender
Common Stock
2021-11-24−6,043→ 0 total(indirect: MDV ENF VII (A), L.P.) - Disposition from Tender
Common Stock
2021-11-24−25,661→ 0 total(indirect: MDV VII Leaders' Fund, L.P.)
Footnotes (10)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").
- [F10]$2.89 plus two CVRs per share underlying the stock option.
- [F2]A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.
- [F3]Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
- [F4]Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
- [F5]Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
- [F6]The stock option is fully vested and exercisable.
- [F7]Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
- [F8]$3.30 plus two CVRs per share underlying the stock option.
- [F9]$5.40 plus two CVRs per share underlying the stock option.
Documents
Issuer
Adamas Pharmaceuticals Inc
CIK 0001328143
Entity typeother
Related Parties
1- filerCIK 0001503381
Filing Metadata
- Form type
- 4
- Filed
- Nov 23, 7:00 PM ET
- Accepted
- Nov 24, 4:09 PM ET
- Size
- 24.4 KB